This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): rizatriptan benzoate, MK-0462
Description: Maxalt binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors. Maxalt hasweak affinity for other 5-HT1 receptor subtypes (5-HT1A, 5-HT1E, 5-HT1F) and the 5-HT7 receptor, but hasno significant activity at 5-HT2, 5-HT3, alpha- and beta-adrenergic, dopaminergic, histaminergic,muscarinic or benzodiazepine receptors.
The therapeutic activity of Maxalt in migraine can most likely be attributed to agonist effects at 5-HT1B/1D receptors on the extracerebral, intracranial bloodvessels that become dilated during a migraine attack and on nerve terminals in the trigeminal system.Activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release andreduced transmission in trigeminal pain pathways.
Pink Sheet Maxalt Paragraph IV Filing
Additional information available to subscribers only: